Compare F5 Inc (FFIV) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Halozyme Therapeutics Inc. Common Stock — how do they compare? F5 Inc trades at $479.83 (market cap $26.14B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: F5 Inc is far larger — about 2.1× Halozyme Therapeutics Inc. Common Stock's market cap, and F5 Inc is trading nearer its 52-week high, Halozyme Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| FFIV | HALO | |
|---|---|---|
Market Cap | $26.14B | $12.58B |
Volume | 503,146 | 2,179,278 |
Sector | Technology | Health |
52-Week High | $469.79 | $115.22 |
52-Week Low | $223.99 | $61.63 |
Typical Hold Time | 38 Days | 1 Days |
Enterprise Value | $24.78B | $14.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $461.66, down 1.07% on the day, with a bullish technical outlook supported by moving averages and a strong fundamental backdrop. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.73 surpassing the $4.00 expectation. Revenue and net income have shown steady growth, reaching $3.09 billion and $692.38 million in 2025, respectively. Positive sentiment is fueled by recent strategic partnerships and industry recognitions, such as being named a Leader in the IDC MarketScape for WAAP platforms.
The stock's valuation appears elevated with a P/E of 36.78 and P/S of 8.07, posing a risk if growth moderates. Analyst consensus is mixed with a $416.60 price target below the current price, suggesting caution despite a majority Hold rating. Key investment opportunities include continued execution on AI security initiatives, while risks involve competitive pressures and reliance on enterprise spending. The stock's proximity to resistance at $468 warrants monitoring for breakout or pullback signals.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
